These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 35187628)

  • 61. Evaluating the long-term cost-effectiveness of liraglutide versus exenatide BID in patients with type 2 diabetes who fail to improve with oral antidiabetic agents.
    Valentine WJ; Palmer AJ; Lammert M; Langer J; Brändle M
    Clin Ther; 2011 Nov; 33(11):1698-712. PubMed ID: 22018679
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Cost-Utility Analysis of Dapagliflozin Compared to Sulfonylureas for Type 2 Diabetes as Second-Line Treatment in Indian Healthcare Payer's Perspective.
    Bagepally BS; Chaikledkaew U; Youngkong S; Anothaisintawee T; Thavorncharoensap M; Dejthevaporn C; Thakkinstian A
    Clinicoecon Outcomes Res; 2021; 13():897-907. PubMed ID: 34712053
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A short-term cost-utility analysis of insulin degludec versus insulin glargine U100 in patients with type 1 or type 2 diabetes in Denmark.
    Pollock RF; Tikkanen CK
    J Med Econ; 2017 Mar; 20(3):213-220. PubMed ID: 27705031
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Budget impact of introducing oral semaglutide to the public healthcare benefit package in Saudi Arabia.
    Alluhidan M; Alabdulkarim H; Alrumaih A; Al-Turaiki A; Alshahrani A; Al-Qahtani S; Alhossan A; Al-Jedai A
    J Med Econ; 2023; 26(1):1455-1468. PubMed ID: 37933169
    [TBL] [Abstract][Full Text] [Related]  

  • 65. First-line Treatment with Empagliflozin and Metformin Combination Versus Standard Care for Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease in Qatar. A Cost-Effectiveness Analysis.
    Abushanab D; Al-Badriyeh D; Liew D; Ademi Z
    Curr Probl Cardiol; 2022 Jun; 47(6):100852. PubMed ID: 33992426
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Cost-Effectiveness of iGlarLixi Versus Premix BIAsp 30 in Patients with Type 2 Diabetes Suboptimally Controlled by Basal Insulin in the UK.
    McCrimmon RJ; Palmer K; Alsaleh AJO; Lew E; Puttanna A
    Diabetes Ther; 2022 Jun; 13(6):1203-1214. PubMed ID: 35543869
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Cost-Effectiveness Analysis of Exenatide versus GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus.
    Capel M; Ciudin A; Mareque M; Rodríguez-Rincón RM; Simón S; Oyagüez I
    Pharmacoecon Open; 2020 Jun; 4(2):277-286. PubMed ID: 31338828
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Cost-Effectiveness of Dapagliflozin as Add-On to Metformin for the Treatment of Type 2 Diabetes Mellitus in Greece.
    Tzanetakos C; Tentolouris N; Kourlaba G; Maniadakis N
    Clin Drug Investig; 2016 Aug; 36(8):649-59. PubMed ID: 27221806
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The long-term cost-effectiveness of once-weekly semaglutide versus sitagliptin for the treatment of type 2 diabetes in China.
    Gu S; Gu J; Wang X; Wang X; Li L; Gu H; Xu B
    Health Econ Rev; 2024 Apr; 14(1):26. PubMed ID: 38564113
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Healthcare Resource Utilization and Costs for Empagliflozin Versus Glucagon-Like Peptide-1 Receptor Agonists in Routine Clinical Care in Denmark.
    Thomsen RW; Christensen LWB; Kahlert J; Knudsen JS; Ustyugova A; Sandgaard S; Holmgaard P; Ehlers LH; Sørensen HT
    Diabetes Ther; 2022 Dec; 13(11-12):1891-1906. PubMed ID: 36315384
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Cost-effectiveness of sensor-augmented pump therapy versus standard insulin pump therapy in patients with type 1 diabetes in Denmark.
    Roze S; de Portu S; Smith-Palmer J; Delbaere A; Valentine W; Ridderstråle M
    Diabetes Res Clin Pract; 2017 Jun; 128():6-14. PubMed ID: 28432898
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Calibration of the IQVIA Core Diabetes Model to the stroke outcomes from the SUSTAIN 6 cardiovascular outcomes trial of once-weekly semaglutide.
    Berry S; Chubb B; Acs A; Falla E; Verma A; Malkin SJP; Hunt B; Palmer AJ
    J Med Econ; 2023; 26(1):1019-1031. PubMed ID: 37525970
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
    Thein D; Christiansen MN; Mogensen UM; Bundgaard JS; Rørth R; Madelaire C; Fosbøl EL; Schou M; Torp-Pedersen C; Gislason G; Køber L; Kristensen SL
    Cardiovasc Diabetol; 2020 Jul; 19(1):107. PubMed ID: 32631337
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Cost-effectiveness of metformin plus vildagliptin compared with metformin plus sulphonylurea for the treatment of patients with type 2 diabetes mellitus: a Portuguese healthcare system perspective.
    Viriato D; Calado F; Gruenberger JB; Ong SH; Carvalho D; Silva-Nunes J; Johal S; Viana R
    J Med Econ; 2014 Jul; 17(7):499-507. PubMed ID: 24708176
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Long-Term Cost-Effectiveness Analysis of Once-Weekly Semaglutide versus Dulaglutide in Patients with Type 2 Diabetes with Inadequate Glycemic Control in China.
    Ruan Z; Ung COL; Shen Y; Zhang Y; Wang W; Luo J; Zou H; Xue Y; Wang Y; Hu H; Guo L
    Diabetes Ther; 2022 Oct; 13(10):1737-1753. PubMed ID: 35934763
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Cost-effectiveness analysis of metformin+dipeptidyl peptidase-4 inhibitors compared to metformin+sulfonylureas for treatment of type 2 diabetes.
    Kwon CS; Seoane-Vazquez E; Rodriguez-Monguio R
    BMC Health Serv Res; 2018 Feb; 18(1):78. PubMed ID: 29391064
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Choice across 10 pharmacologic combination strategies for type 2 diabetes: a cost-effectiveness analysis.
    Gu S; Shi L; Shao H; Wang X; Hu X; Gu Y; Dong H
    BMC Med; 2020 Dec; 18(1):378. PubMed ID: 33267884
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Semaglutide vs Endoscopic Sleeve Gastroplasty for Weight Loss.
    Haseeb M; Chhatwal J; Xiao J; Jirapinyo P; Thompson CC
    JAMA Netw Open; 2024 Apr; 7(4):e246221. PubMed ID: 38607627
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Comparative value of dapagliflozin vs empagliflozin in patients with heart failure and preserved ejection fraction: A cost-effectiveness analysis.
    Rane A; Nechi RN; Imam M; Zoni CR; Ndikumukiza C; Karaye IM; Yunusa I; Alanzi A
    J Manag Care Spec Pharm; 2023 Sep; 29(9):1045-1053. PubMed ID: 37610112
    [No Abstract]   [Full Text] [Related]  

  • 80. Cost-effectiveness of empagliflozin as a treatment for heart failure with reduced ejection fraction: an analysis from the Chinese healthcare perspective.
    Lin X; Lin M; Liu M; Huang W; Nie X; Chen Z; Zheng B
    J Thorac Dis; 2022 May; 14(5):1588-1597. PubMed ID: 35693603
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.